Skip to content

Gerber Laboratory

The Gerber lab seeks to bridge the gap between the basic science of glucocorticoid receptor (GR) biology, and clinical therapeutics in pulmonary disease. To accomplish this, we are investigating two basic aspects of glucocorticoid action in the lung. In one area of study, we are investigating the lung-specific function of two members of the Kruppel-like family of transcription factors that are regulated by glucocorticoids, Klf9 and Klf15. In another approach, we are decoding the primary and secondary transcriptional responses to glucocorticoids in airway cells. Through developing a greater understanding of these two aspects of GR function, we seek to identify novel candidates for therapeutic targeting to treat lung disease.


Lab Resources and Services

The Gerber laboratory is located on the 6th floor of the Goodman building on the main campus of National Jewish Health. Learn more.


Current Projects


Anthony N. Gerber

Anthony N. Gerber, MD, PhD




Gally F, Sasse SK, Kurche JS, Gruca MA, Cardwell JH, Okamoto T, Chu HW, Hou X, Poirion OB, Buchanan J, Preissl S, Ren B, Colgan SP, Dowell RD, Yang IV, Schwartz DA, Gerber AN. The MUC5B-associated variant rs35705950 resides within an enhancer subject to lineage- and disease-dependent epigenetic remodeling. JCI Insight. 2021;6(2). Abstract

Mostafa MM, Bansal A, Michi AN, Sasse SK, Proud D, Gerber AN, Newton R. Genomic determinants implicated in the glucocorticoid-mediated induction of KLF9 in pulmonary epithelial cells. J Biol Chem. 2020. Abstract

More Publications